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Skin-derived antileukoproteinase, also described as 
elafin or as elastase specific inhibitor, is a serine pro­
teinase inhibitor which is thought to play a regulatory 
role in inflammation. Research in the last few years 
has increased our knowledge on the structural, 
biochemical, and cell biological aspects of this 
molecule, Here we will review the most relevant litera­
ture presently available on this proteinase inhibitor. 
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Introduction
Proteinases derived from polymorphonuclear leukocytes 
(PMNs) such as elastase, cathepsin G, proteinase 3, and 
collagenase can cause severe tissue damage by degrad­
ing a wide variety of macromoiecular substrates (Weiss*
1989). In order to control proteolysis by these proteinases, 
a number of highiy effective proteinase inhibitors is known 
to be present in the extracellular space which are abie to 
limit the proteolytic activity of these enzymes (Feinstein, 
1984). Several inhibitors of PMN-derived elastinolytic en­
zymes have previously been described. Two main inhibi­
tors, arproteinase inhibitor and a2-macroglobulin, are 
present in plasma (Travis and Saivesen, 1983). One locally 
synthesized inhibitor, antileukoproteinase (ALP), is also 
known as secretory leukocyte proteinase inhibitor (SLPI) 
or mucus proteinase inhibitor (MPI) (Heinzel et a/., 1986; 
Thompson and Ohlsson, 1986; Fritz, 1988).
In 1987 our group observed induction of an elastase in­
hibiting activity in normal human skin as a response to in­
jury (Chang et a/M 1988). This anti-elastase activity was 
later found to be present in several scaling skin disorders 
(Chang et a/„ 1990), The inhibitor could be purified from 
psoriatic epidermis and from cultured human keratino­
cytes and was distinct from other known elastase inhibi­
tors (Schalkwijk et &Lt 1990; Schalkwijk et aLt 1991). 
Based on partial sequence homology with ALP, we named 
this molecule skin-derived antileukoproteinase (SKALP).
Two molecules with properties very similar to SKALP were 
described independently by other groups: elafin by 
Wiedow and colleagues (Wiedow et al., 1990) and elas- 
tase-specific inhibitor (ESI) by Sallenave and Ryle (1991). 
In retrospect we believe that the sputum-derived 
molecules described as bronchial secretion inhibitor 
(BSI-E) by Hochstrasser and colleagues (Hochstrasser et 
a/., 1981) and LMI-5000 (low molecular weight inhibitor of 
5000 Da) by Kramps and Klasen (1985) represent the 
same inhibitor as ESI, and should hence be considered as 
the first description of what is now generally named 
SKALP or elafin.
In the last few years, research has focussed on the 
elucidation of the structural and biochemical properties of 
SKALP. Recently, immunohistological and cell biological 
studies have given more insight in the localization and tis­
sue distribution of SKALP, and in the induction of SKALP 
gene expression. Here we will review the presently availa­
ble literature of SKALP/elafin/ESI, Throughout this paper 
we will use the name SKALP to refer to this molecule.
Structural Aspects of SKALP
SKALP activity was shown to be high in psoriatic scales 
which were used as a convenient source for purification of 
the molecule (Schalkwijk etaln 1990; Wiedow etalu 1990). 
SKALP purified from psoriatic scales was used to obtain 
the complete sequence of a 6 kDa fragment (Wiedow et 
a/., 1990) and a partial internal sequence (Schalkwijk et 
a/., 1991) which indicated that they represented the same 
molecule, Sallenave and colleagues published a partial 
amino acid sequence of ESI purified from sputum (Sal­
lenave et a/., 1992) suggesting that ESI, SKALP, and elafin 
were the same molecule.
In cultured human keratinocytes we found an elastase 
inhibitor with an apparent molecular mass of about 18 
kDa on SDS-PAGE. This inhibitor was otherwise indistin­
guishable from SKALP derived from psoriatic scales 
using biochemical and immunochemical criteria 
(Schalkwijk e ta/., 1990; Schalkwijk etal., 1991).This led us 
to the hypothesis that the molecule synthesized in cul­
tured human keratinocytes is a larger precursor molecule 
of the low molecular weight form found in psoriatic 
scales. We therefore purified SKALP from cultured human 
keratinocytes, followed by aminoterminal sequencing, 
and we cloned the SKALP encoding cDNAfrom a human 
keratinocyte cDNA library (Molhuizen et a/.t 1993). The re­
sults showed that SKALP in cultured human keratino-
2 H.O.F. Molhuizen and J. Schalkwijk
cytes is synthesized as a precursor molecule, consisting 
of 117 amino acids including a hydrophobic signal peptide 
of 22 amino acids. The presence of this hydrophobic 
leader suggests that translation of SKALP takes place at 
the rough endoplasmic reticulum (von Heijne, 1988). 
Cleavage of this signal peptide results in a mature protein 
of 95 amino acids with a calculated molecular mass of 9.9 
kDa as determined by aminoterminal gas phase sequenc­
ing. The aminoterminal parts of SKALP and ALP show no 
significant homology but the carboxyterminal part of ALP 
shows approximately 40% homology with the car­
boxyterminal part of SKALP. Also, 100% identity was 
found with a stretch of 6 amino acids in the carboxytermi­
nal part of ALP. Interestingly, this sequence is part of the 
active site of ALP, located in the second domain (Kramps 
et a/., 1990). Based on the homology between parts of 
SKALP and ALP we denoted the carboxyterminal part of 
the mature SKALP molecule, spanning 50 amino acids, as 
being the proteinase inhibiting domain (Molhuizen eta l, 
1993). A partial cDNA sequence and the production of re­
combinant SKALP (57 carboxyterminal amino acids) has 
also been reported in a patent application which covers 
the pharmaceutical use of SKALP (Christophers et al.,
1990).
The aminoterminal part of the mature 9.9 kDa SKALP 
protein isolated from cultured human keratinocytes con­
tains four repeats which match remarkably well with a 
consensus sequence for transglutaminase cross-linking, 
first described in seminal vesicle protein I from guinea pig 
(Moore eta/., 1987; Hagstrom et a/., 1989). Covalent dot­
ting of this protein is catalyzed by a transglutaminase, as 
will be discussed later. Based on this striking homology 
we surmised that this region can act as a putative sub­
strate domain for epidermal transglutaminase (Molhuizen 
etal., 1993).
The positions of 8 cysteine residues present in the pro­
teinase inhibiting region are highly conserved. Small pro­
teins showing this characteristic have been called ‘four- 
disulfide core’ proteins (Drenth etal., 1980). Several pro­
teins belong to this group, like whey acidic protein (Hen- 
nighausen et a/., 1982), the sodium potassium ATPase 
inhibitors 1, 2 and 3 (Araki et a/., 1990) and ALP/SLPI 
(Seemuller etal., 1986; Thompson and Ohlsson, 1986). 
Grutter and colleagues were the first to describe the con­
nectivity pattern of the 4 disulfide bridges in ALP/SLPI as 
resolved by tertiary structure analysis (Grutter et a/., 
1988). In chemically synthesized elafin the 8 cysteine re­
sidues were also shown to be involved in the forming of 4 
disulfide bonds by Tsunemi and colleagues (Tsunemi et 
al.f 1992). From their experiments it could be concluded 
that disulfide linkages have to be formed as shown in Fig­
ure 1 in order to obtain elastase inhibiting activity. Using 
truncated peptides it was also shown in the same paper 
that the aminoterminal part of the molecule plays an im­
portant role in forming the correct disulfide bonds, but 
may not be essential for expressing full inhibitory activity.
The SKALP gene was isolated independently by several 
groups. Saheki and colleagues screened a human
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Fig. 1 Deduced Disulfide Structure for Synthetic Elafin.
genomic DNA library with a porcine sodium-potassium 
ATPase inhibitor (SPAI) cDNA probe under moderate 
stringency conditions (Saheki etal., 1992). Due to the par­
tial homology between SKALP and SPAI they were able to 
isolate the human elafin gene. Their results were con­
firmed by Sallenave and colleagues, who previously 
showed elafin to be synthesized by lung-derived cell lines 
(Sallenave and Ryle, 1991; Sallenave et a/., 1992; Sal­
lenave et a/., 1993b) and cloned the human elafin gene 
using a cDNA clone encoding the 57 amino acids of elafin 
(Sallenave and Silva, 1993a). Our group used a SKALP 
cDNA probe and obtained a clone containing the com­
plete SKALP gene (Molhuizen ef a/., 1994). The SKALP 
gene is approximately 1.7 kbp long and contains 3 exons 
and 2 introns. All the exon-intron junctions confirm to the 
AG-GT consensus sequence (Mount, 1982). The first exon 
contains the 5'-noncoding region and the first 79 nucleo­
tides of the coding sequence, encoding the hydrophobic 
signal sequence as well as the first 4 amino acids of the 
mature protein. The second exon encodes the rest of the 
protein and the first nucleotide of the 3'-noncoding re­
gion. The rest of the 3'-noncoding region, including the 
polyadenylation signal, is completely encoded by the 
third exon (Figure 2).
The 5'-noncoding region contains both aTATA-box and 
a CCAAT-box, found 94 bp and 120 bp upstream of the 
translational start site respectively. The sequence preced­
ing the proposed translational start site matches well with 
the consensus sequence for strong eukaryotic initiation 
of translation (Kozak, 1987). Interestingly, the 5'-noncod- 
ing region contains a small open reading frame consisting 
of 33 nucleotides. This is remarkable since translation of 
eukaryotic mRNAs usually starts at the first AUG (Kozak, 
1983). Whether this small open reading frame is translated 
and, if so, what the functional role of the resulting peptide 
might be, is not clear. Only 5-10% of vertebrate mRNAs 
have upstream AUG codons, many of them being pro­
tooncogenes, growth-control genes and receptor genes 
(Kozak, 1989; Marth et a/M 1988; Dixon et aL, 1986). The
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Fig. 2 Schematic Representation of the Organization of the 
SKALP Gene and the Resulting cDNA. 
a: hydrophobic signal sequence encoding region {22 amino 
acids), b: transglutaminase substrate domain encoding region 
(45 amino acids), c: proteinase inhibiting domain encoding re­
gion (50 amino acids).
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role of these upstream AUG codons is not clear in higher 
eukaryotes, but in yeast it has been shown that upstream 
AUGs can repress the efficiency of translation initiation of 
the long downstream open reading frame, and thus play a 
role in the regulation of translation (Hunt, 1985; Cigan and 
Donahue, 1987).
Recently we used our genomic SKALP DNA clones to 
establish the chromosomal localization of the SKALP 
gene (Molhuizen et al., 1994). Using Southern blot 
analysis of a panel of human x hamster hybrid cell lines 
and by nonradioactive in s/Yt/ hybridization on R-banded 
human lymphocyte chromosome spreads, we were able 
to locate the SKALP gene at human chromosome 20, re­
gion q12—>q13. The SKALP encoding gene has been as­
signed the approved symbol PI3 by the Human Gene 
Mapping nomenclature committee. To our knowledge, no 
skin disease has so far been mapped to this region of 
chromosome 20. Interestingly, a cluster of other pro­
teinase inhibitors expressed in epidermis, the cystatins, 
have been mapped to the same chromosomal region 
(McKusick, 1992). Although no structural homology was 
found between SKALP and the cystatins, they share a 
curious functional property in that they can all act as 
transglutaminase substrates. Both SKALP and cystatin « 
were found to be cross-linked to stratum corneum pro­
teins (Takahashi e ta/., 1992; Molhuizen etal., 1993).
Synthetic elafin (57 amino acids) has recently been 
crystallized in complex with porcine pancreatic elastase. 
The crystals belong to the monoclinic space group P2\. 
The crystals, which diffract X-rays to a resolution of 1,9 A, 
will be used to elucidate the mode of complex formation 
by the X-ray diffraction method (Tsunemi et a/,t 1993). 
As yet, no crystallographic studies on the 3-D structure 
and interaction sites of SKALP with elastase or trans­
glutaminase have been published.
Biochemical Properties
Extraction and purification of active SKALP involved boil­
ing of homogenates of psoriatic scales and the use of buf­
fers ranging from pH 3.0 to 11,0 (Schalkwijk et al., 1991; 
Wiedow et a/., 1990), indicating that SKALP is a very heat 
stable and pH stable molecule. Furthermore, SKALP was 
found to be very cationic with a calculated isoelectric 
point of 8.84 (Molhuizen et a/., 1993), The strong cationic 
nature of this molecule probably explains the significant 
deviation of the apparent molecular mass found on SDS- 
PAGE from the calculated molecular mass, since strongly 
cationic proteins migrate much slower on SDS-PAGE.
SKALP was shown to be a specific inhibitor of human 
leukocyte elastase (HLE), porcine pancreatic elastase, 
and proteinase 3 but it does not inhibit the serine pro- 
teinases cathepsin G, trypsin, chymotrypsin and plasmin 
(Schalkwijk ef a/., 1990; Schalkwijk et al., 1991; Wiedow et 
a/„ 1991; Wiedow e t a l 1993;Tsunemi eta/., 1992).The in­
hibitory activities of chemically synthesized elafin are in 
the same range as found for the natural molecule yielding
dissociation constants (Kj) of 6 x 10“ 10M to 2 x 10~n M 
for HLE, and 1 x 10~9m for porcine pancreatic elastase 
(Wiedow et al., 1990; Tsunemi et al.} 1992; Ying and 
Simon, 1993). Elafin is also a potent inhibitor of proteinase 
3, with a Ki of 9.5 x 10~9m (Wiedow eta/., 1991; Wiedow et 
a/., 1993). The kinetics of inhibition of HLE by elafin were 
extensively investigated by Ying and Simon. Their findings 
indicate that a single inhibitor molecule binds to a single 
site on the proteinase, blocking the reactive serine at the 
enzyme’s catalytic center. Association of the enzyme with 
the inhibitor proceeds via a single bimolecular process, 
with a second-order rate constant of 3,6 x 106 M“1 s " 1 at 
pH 8.0 and 25 °C. Dissociation of the enzyme-inhibitor 
complex regenerates the inhibiting activity with at least 
99.8%, showing that elafin is a fully reversible inhibitor. 
The K\ of the enzyme-inhibitor complex was found to de­
crease from 6.7 x 10~9 to 2.0 x 10"1oM as the pH is in­
creased from 5.4 to 9.0, revealing that the reaction rate is 
dependent on the concentration of the unprotonated 
form of a group with a pKa of 6.8, which was assigned to 
the histidine in the enzyme’s active site (Ying and Simon, 
1993).
As mentioned before, the aminoterminal part of the ma­
ture SKALP protein contains 4 repeats which show signif­
icant homology with a consensus sequence for trans­
glutaminase cross-linking (Figure 3) described in seminal 
vesicle protein I from guinea pig (Moore ef a/„ 1987; 
Hagstrom et a/., 1989). Transglutaminase catalyzes the 
covalent clotting of this protein, involving the formation of 
y-glutamyl-e-lysine cross-links. Three residues in these 
repeats, 2 lysines and 1 glutamine, are thought to partici­
pate in the cross-links. It was clearly shown that SKALP 
can indeed become cross-linked by transglutaminase to 
proteins extracted from psoriatic scales and it is specu­
lated that SKALP can exist as an immobilized 9.9 kDa pro­
tein, covalently attached to the cornified envelopes by 
transglutaminase cross-linking (Molhuizen et a/M 1993). 
Immunohistochemical staining of psoriatic epidermis 
suggests that at least part of the SKALP present in the 
epidermis is indeed closely associated to the cornified en­
velopes (Schalkwijk eta/., 1993).
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Fig. 3 Comparison of Four Repeats in the Putative Transgluta­
minase Substrate Domain with the Supposed Consensus Se­
quence for Transglutaminase Cross-Linking,
Identical amino acids are marked. Numbering is according to the 
SKALP cDNA clone pGESKA (Molhuizen eta/,, 1993).
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Sallenave and colleagues reported the secretion of 
SKALP by the NCI-H322 and A549 lung carcinoma cell 
lines which have features of Clara cells and type J) 
pneumocyte cells (Sallenave etal., 1993b). SKALP, as well 
as SLPI, were secreted by cells either in serum-free or 
serum-containing media. Depending on the cell iine and 
the culture conditions two immunoreactive SKALP 
species were detected. In a second study it was found 
that in these cell lines, SKALP is induced by leukocyte 
elastase, interleukin-1 beta and tumor necrosis factor 
(Sallenave etal, 1994). These findings suggest that airway 
epithelial cells may respond to cytokines secreted during 
the onset of inflammation by increasing their antipro­
teinase shield. Analogous to the situation in skin, SKALP 
appears to act as a local acute phase reactant in lung tis­
sue as well.
acts as an inhibitor of leukocyte derived proteinases, and 
is hence involved in regulation of inflammation. Cell 
biological and clinical studies are in support of this view. 
In a number of normal epithelia (oral epithelia, esophagus, 
vagina) SKALP is constitutively expressed. Close exami­
nation of these tissues reveals that a low grade of PMN in­
filtration is physiological in these areas of the body. Skin 
represents a special case, since SKALP is inducible in 
epidermis upon trauma or inflammation. Therefore, skin is 
an excellent model to study the mechanisms involved in 
induction and regulation of SKALP gene expression. Fu­
ture studies on SKALP will focus on the elucidation of the 
normal physiological functions of this molecule and its 
role in the pathophysiology of inflammatory conditions in 
various epithelia.
Clinical Studies
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Alkemade and colleagues described the presence of high 
SKALP levels in urine from psoriatic patients, using a 
functional assay (Alkemade et al„ 1992), The levels in 
urine of normal controls were below the detection level of 
the assay used. Streit and colleagues confirmed the pres­
ence in urine of psoriatic patients and demonstrated 
SKALP in urine from patients with various inflammatory 
skin diseases. Recently we have studied SKALP levels in 
serum of psoriatic patients and healthy controls using an 
ELISA (Alkemade et a/., unpublished results). We found 
that normal control sera contain 10.6 ± 5.9 ng SKALP per 
ml, which probably reflects the turnover of SKALP from 
normal tissues as esophagus and oral epithelia. In serum 
from psoriatic patients we found a 3 to 20-fofd increase in 
SKALP serum levels. In a study of 6 patients with severe 
psoriasis treated with cyclosporin-A we found that the de­
crease in serum SKALP levels correlated with clinical im­
provement, as measured with the Psoriatic Area and Sev­
erity Index (PASI) score.
The expression of SKALP in various types of psoriasis 
was also studied by our group. In a case study of a patient 
with annular pustular psoriasis we demonstrated the 
rapid induction and downregulation of SKALP in vivo 
(Kuijpers etaL, 1994), When patients with pustular forms 
of psoriasis (palmoplantar and generalized) were com­
pared with plaque type psoriasis, we found a significant 
decrease (70%) of SKALP activity in scale extracts of the 
pustular psoriasis group (Kuijpers et a/., unpublished re­
sults). Whether this deficiency has a genetic basis, or is a 
consequence of the disease process remains to be inves­
tigated.
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